Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Latvia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,321 result(s) found for: Latvia. Displaying page 5 of 67.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-004440-19 Sponsor Protocol Number: CLAM320B2202 Start Date*: 2016-03-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regi...
    Medical condition: Treatment of multidrug-resistant pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10070578 Multidrug resistant tuberculosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004546-26 Sponsor Protocol Number: VIS410-202 Start Date*: 2017-01-11
    Sponsor Name:Visterra, Inc.
    Full Title: A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects with Uncomplicated Influenza A Infection
    Medical condition: Influenza A infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-000492-33 Sponsor Protocol Number: BY1023/M3-904 Start Date*: 2004-09-06
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000653-23 Sponsor Protocol Number: TMC207-TiDP13-C210 Start Date*: 2012-06-13
    Sponsor Name:Janssen Infectious Diseases BVBA
    Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc...
    Medical condition: Multi-drug resistant tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-000406-30 Sponsor Protocol Number: 3071-305-020 Start Date*: 2020-07-13
    Sponsor Name:Allergan Limited
    Full Title: Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003298-90 Sponsor Protocol Number: OPT-302-1003 Start Date*: 2018-12-07
    Sponsor Name:Opthea Ltd
    Full Title: Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema
    Medical condition: Persistent central-involved diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2017-004098-15 Sponsor Protocol Number: DS107G-04-UP1 Start Date*: 2018-01-30
    Sponsor Name:DS Biopharma
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Se...
    Medical condition: Moderate to Severe Uremic Pruritus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004571-41 Sponsor Protocol Number: RBMinCovid19 Start Date*: 2021-02-23
    Sponsor Name:Cyxone AB
    Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)
    Medical condition: Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003326-23 Sponsor Protocol Number: DT-DP-DFU-CR-05 Start Date*: 2021-07-05
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers
    Medical condition: 3. Diabetic foot ulcer treated unsuccessfully for at least 4 weeks with mean diameter between 1.5 and 4 cm after débridement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003991-56 Sponsor Protocol Number: OPH2003 Start Date*: 2016-04-15
    Sponsor Name:IVERIC bio
    Full Title: A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary t...
    Medical condition: Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075567 Dry age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) EE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001634-18 Sponsor Protocol Number: M602011072 Start Date*: Information not available in EudraCT
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo...
    Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    21.1 100000004852 10024132 Leg spasticity LLT
    20.1 100000004850 10021740 Infantile cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002168-26 Sponsor Protocol Number: ML27880 Start Date*: 2012-01-05
    Sponsor Name:Roche (Magyarország) Kft.
    Full Title: OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (E...
    Medical condition: Open label study of erlotinib (Tarceva®) as single agent first line treatment of patients with locally advanced or metastatic lung adenocarcinoma with activating Epidermal Growth Factor Receptor (E...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-000091-14 Sponsor Protocol Number: FFR102123 Start Date*: 2004-09-17
    Sponsor Name:GlaxoSmithKline, S.A
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg ...
    Medical condition: Perennial allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) LV (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000406-51 Sponsor Protocol Number: EMD20001 Start Date*: 2004-09-16
    Sponsor Name:GlaxoSmithKline
    Full Title: A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment o...
    Medical condition: Suspected or Confirmed Gram-negative Severe Sepsis in Adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) CZ (Completed) LV (Completed) AT (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006668-25 Sponsor Protocol Number: BM12H-PSO-03-G-02 Start Date*: 2022-07-12
    Sponsor Name:Biocon Biologics UK Limited
    Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara® in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005974-91 Sponsor Protocol Number: CT-P41_3.1 Start Date*: 2021-04-26
    Sponsor Name:Celltrion, Inc
    Full Title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteop...
    Medical condition: Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increas...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003776-13 Sponsor Protocol Number: ALN-AGT01-003 Start Date*: 2021-12-15
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled b...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000696-16 Sponsor Protocol Number: SEP361-303 Start Date*: 2019-09-06
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001064 Acute schizophrenia LLT
    20.0 100000004873 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004493-25 Sponsor Protocol Number: FFR106080 Start Date*: 2006-01-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003883-28 Sponsor Protocol Number: SB15-3001 Start Date*: 2020-05-28
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eyl...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 10:03:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA